Loading company…
Cambridge-based developer of breath analysis tests for early detection of cancer and respiratory conditions.
Owlstone Medical, Ltd. develops non-invasive diagnostic tests that analyze volatile organic compounds in exhaled breath, including the Breath Biopsy and the ReCIVA Breath Sampler. Founded in 2004 in Cambridge, UK, by Billy Boyle and David Alonso, the company has completed 10 deals and raised EUR 1.7 million from the Cystic Fibrosis Foundation on March 25, 2025. Bret Bader is CEO, and the company reported revenue of GBP 4,080,096.80 and EBITDA of GBP -28,140,923.40 for 2024. It is at the Series E stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in